8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
Apr 7, 2026·SEC
Material company update
Mar 26, 2026·SEC
Inhibikase Therapeutics, Inc.(IKT)Earnings, Financials & Key Ratios
IKT•NASDAQ
$1.91
Price updated Jun 27, 2026
AboutInhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.Show more
- Revenue$0
- EBITDA-$52M-81.8%
- Net Income-$48M-75.4%
- EPS (Diluted)-0.49+57.8%
- ROE-36.05%+30.7%
IKT Price & Volume
Inhibikase Therapeutics, Inc. (IKT) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Outpace Revenue Generation Potential
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Healthy
Cash Flow:Burning
Primary Risk:Clinical trial execution failure
Key Thesis Takeaways
- Inhibikase Therapeutics remains a pre-revenue biotechnology firm entirely dependent on the successful advancement of its RAMP platform to generate future enterprise value.
- While the company maintains a debt-free balance sheet with $49.6 million in cash as of 2026Q1, the rapid escalation of quarterly net losses to $16.4 million underscores significant execution risk.
- Investors should monitor the sustainability of this cash runway as the firm navigates capital-intensive clinical trials without a commercial product to offset rising R&D expenditures.
Verdict Logic
the company's reliance on equity-based funding and the absence of revenue, combined with a quarterly net loss of $16.4 million, suggests substantial dilution risk for shareholders.
IKT Growth Metrics
Inhibikase Therapeutics, Inc. (IKT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-39.43%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM66.87%
Return on Capital
10 Years-72.55%
5 Years-67.77%
3 Years-72.39%
Last Year-38.82%
IKT Recent Earnings
Inhibikase Therapeutics, Inc. (IKT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.10+0.0%
$0.10
Rev
—
—
Q2 2026
Mar 26, 2026Metric
Actual
Est
EPS
$0.09+25.0%
$0.12
Rev
—
—
Q4 2025
Nov 14, 2025Metric
Actual
Est
EPS
$0.13+0.0%
$0.13
Rev
—
—
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.11-22.2%
$0.09
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.10vs $0.10+0.0% | — |
| Q2 2026 | Mar 26, 2026 | $0.09vs $0.12+25.0% | — |
| Q4 2025 | Nov 14, 2025 | $0.13vs $0.13+0.0% | — |
| Q3 2025 | Aug 14, 2025 | $0.11vs $0.09-22.2% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Inhibikase Therapeutics, Inc. (IKT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.91 | $135.62M | -3.90 | — | — | -36.05% | — | |
| $10.02 | $524.58M | -2.21 | -92.84% | -260.92% | -49.88% | — | |
| $25.32 | $4.34B | 11.06 | 11.87% | 34.3% | 35.65% | — | |
| $1.32 | $63.77M | -2.54 | — | — | -95.77% | — | |
| $3.73 | $64.48M | -2.78 | — | -1070.26% | — | — | |
| $23.57 | $1.74B | 7.14 | 18.52% | 118.91% | 47.59% | — |
Compare IKT vs Peers
Inhibikase Therapeutics, Inc. (IKT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
IKT SEC Filings & Documents
Inhibikase Therapeutics, Inc. (IKT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when IKT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
IKT Frequently Asked Questions
Inhibikase Therapeutics, Inc. (IKT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is IKT profitable?
Inhibikase Therapeutics, Inc. (IKT) reported a net loss of $51.0M for fiscal year 2025.
Dividend & Returns
What is IKT's return on equity?
Inhibikase Therapeutics, Inc. (IKT) has a return on equity (ROE) of -36.0%. Negative ROE indicates the company is unprofitable.
What is Inhibikase Therapeutics, Inc.'s free cash flow?
Inhibikase Therapeutics, Inc. (IKT) had negative free cash flow of $36.2M in fiscal year 2025, likely due to heavy capital investments.